|

A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

RECRUITINGPhase 1Sponsored by Outpace Bio, Inc.
Actively Recruiting
PhasePhase 1
SponsorOutpace Bio, Inc.
Started2026-06-30
Est. completion2030-06
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
Locations5 sites

Summary

The goal of this clinical trial is to learn if OPB-201 is safe in recurrent endometrial and platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-201. Participants will have their own T cells modified in a laboratory and given back to them as OPB-201 in this one-time treatment. Participants will be in the hospital when they receive OPB-201 and then be checked at the clinical site frequently for the first few months.

Eligibility

Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

1. Age ≥ 18 years of age at the time of signing the informed consent form.
2. Histologically confirmed diagnosis of endometrial cancer, epithelial ovarian, peritoneal, or fallopian tube cancer based on local histopathological findings.
3. Received at least 1 prior line of systemic chemotherapy including a platinum-based chemotherapy.
4. Received prior therapy with a PARP inhibitor if the subject has a known germline or somatic BRCA1/2 mutation.
5. Measurable disease.
6. Consent to provide archived tumor tissue sample.
7. ECOG performance status of 0 or 1.
8. Adequate organ function.
9. HLA-A \*02:01 or HLA-A \*02:02
10. PRAME positive tumor

Exclusion Criteria:

1. Women of child-bearing potential who are pregnant or breastfeeding.
2. Uncontrolled bacterial, fungal, or viral infections.
3. Active infection requiring systemic therapy.
4. Bleeding or thrombotic disorders or at risk for severe hemorrhage.
5. Any form of primary immunodeficiency.
6. Had an allogenic tissue/solid organ transplant.
7. Active autoimmune disease.
8. Concurrent treatment with systemic high dose corticosteroids.
9. Unresolved acute effects of any prior therapy.
10. Other exclusions as stated in the protocol.

Conditions8

Advanced Endometrial CancerCancerEndometrial CancerEndometrial Cancer RecurrentEndometrial CancersOvarian CancerOvarian Cancer RecurrentPlatinum-resistant Ovarian Cancer

Interventions1

Locations5 sites

California

1 site
UCSF - Helen Diller Family Comprehensive Cancer Center
Colan Tizon415-307-1067Colan.Tizon@ucsf.edu

Georgia

1 site
Emory - Winship Cancer Institute
Molly Stoddart404-778-6547molly.stoddart@emoryhealthcare.org

Michigan

1 site
Karmanos Cancer Institute
Detroit, Michigan, 48201
Anh Trinh313-576-9298trinha@karmanos.org

Minnesota

1 site
University of Minnesota
Melissa Geller, M.D.612-624-2620ccinfo@umn.edu

Texas

1 site
MD Anderson Cancer Center
Houston, Texas, 77030
Kelly Rangal713-444-4865kshea@mdanderson.org

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.